ELV stock forecast, quote, news & analysis

Key Takeaways

• ELV stock declined approximately -12% over the past 30 days amid regulatory pressures and sector challenges in Medicare Advantage.
• Over the past quarter, the stock fell around -16%, driven by disappointing 2026 guidance and CMS sanction threats.
• Key drivers include CMS notices for potential Medicare enrollment suspensions, Medicaid margin trough expectations, and analyst price target reductions.
• Despite declines, analysts maintain a consensus Buy rating with an average price target above $380.
• Company reaffirmed 2026 adjusted EPS guidance of at least $25.50 amid ongoing cost trend management.

Elevance Health (ELV) Company Overview and Market Position

Elevance Health, Inc. (ELV) is a leading health benefits company operating in the United States, providing a wide range of health plans including Medicare, Medicaid, and commercial insurance under brands like Anthem Blue Cross Blue Shield. Its core business model centers on managed care services, pharmacy benefits through CarelonRx, and behavioral health via Carelon Services, serving over 45 million members. In the competitive healthcare insurance industry, Elevance holds a strong position as one of the largest providers, particularly in Blue Cross Blue Shield markets across 14 states. This scale supports robust pricing power and data-driven care management, but recent stock price movement reflects vulnerabilities to regulatory changes in Medicare Advantage and Medicaid reimbursement pressures, amplifying sector-wide medical cost trends.

Elevance Health (ELV) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, ELV stock has dropped approximately -12%, trading from around $325 in late February to about $287 currently. The movement has been volatile and trend-driven downward, with sharp declines around early March linked to specific news events.

For the past quarter, the stock declined roughly -16%, from approximately $343 in late December to the current level. Performance was range-bound initially before accelerating lower post-earnings in late January and amid March regulatory developments, underperforming broader market trends in healthcare.

What Drove ELV Stock Price in the Last 30 Days

The primary catalyst for ELV's 30-day decline was a February 27, 2026, notice from the Centers for Medicare & Medicaid Services (CMS) threatening sanctions, including suspension of new enrollments in certain Medicare Advantage-Prescription Drug (MA-PD) plans effective March 31 due to alleged noncompliance with risk adjustment data submission requirements. This triggered an 11.3% single-day drop on March 3, as investors weighed potential revenue impacts from enrollment freezes. Analyst reactions included Mizuho lowering its price target from $413 to $350 on March 11 while maintaining Outperform, reflecting sector sentiment shifts. Broader medical cost pressures and Medicaid eligibility reverifications further eroded confidence, connecting directly to heightened volatility and the downward price trend.

What Drove ELV Stock Performance Over the Last Quarter

The quarter's broader downturn began with Q4 2025 earnings on January 28, where adjusted EPS beat estimates at $3.33 but revenue missed at $49.3 billion, and 2026 guidance disappointed: adjusted EPS of at least $25.50 (below consensus), low single-digit revenue decline, and low double-digit drop in risk-based membership due to portfolio repositioning in Medicare Advantage and commercial risk. Shares plunged 7% post-earnings amid Medicaid margin trough forecasts and elevated cost trends. Cumulative impact intensified with CMS sanctions in early March, regulatory probes into health insurers, and macroeconomic factors like persistent inflation in healthcare costs. Institutional selling and peer underperformance in managed care amplified the sustained bearish momentum.

Trending AI Robots

Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots from hundreds available, each analyzing thousands of tickers across various strategies, timeframes, and performance metrics like win rate, profit factor, and drawdown. These curated bots, updated in real-time, highlight those delivering consistent results in current market conditions, helping traders identify automated tools suited to stocks like ELV amid volatile healthcare trends. Whether focusing on trend-following, mean reversion, or momentum, the section provides transparent stats and backtests. Explore Trending AI Robots to enhance your stock analysis with data-driven automation.

ELV Stock Forecast Drivers: What Investors Should Watch Next

Investors should monitor Q1 2026 earnings around late April for updates on medical loss ratios and membership trends. Key industry developments include CMS sanction resolutions and Medicare Advantage reimbursement policies. Macro factors like healthcare inflation, interest rates, and regulatory probes into insurers will influence sentiment. Strategic moves in Carelon growth, share repurchases, and pricing adjustments amid cost trends represent potential catalysts, while risks from enrollment suspensions and Medicaid redeterminations could pressure near-term performance.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.